Promacta (eltrombopag) costs roughly $123,000 per year for a single patient, placing it firmly in the specialty drug category that strains both insurance plans and out-of-pocket budgets. The price reflects a combination of patent protection, orphan drug exclusivity, a small patient population, and limited competition. Here’s a closer look at each factor and what may change soon.
A Small Patient Pool Keeps Prices High
Promacta treats conditions that affect relatively few people. It’s approved for three distinct uses: chronic immune thrombocytopenia (ITP) in patients who haven’t responded to standard treatments, low platelet counts in people with chronic hepatitis C who need interferon therapy, and severe aplastic anemia. All three are uncommon conditions, and severe aplastic anemia is rare enough that Promacta received an orphan drug designation from the FDA for that indication.
Orphan drug status exists to encourage companies to develop treatments for diseases affecting small populations. The tradeoff is significant: manufacturers get seven years of market exclusivity for each approved orphan indication, along with tax credits on clinical trial costs. Promacta’s orphan exclusivity for first-line severe aplastic anemia doesn’t expire until November 2025. When a drug serves tens of thousands of patients rather than millions, the manufacturer spreads its research, manufacturing, and regulatory costs across far fewer prescriptions, which pushes the per-patient price up dramatically.
Patent Protection Blocks Cheaper Alternatives
Promacta’s tablet formulations are protected by patents that don’t expire until February 2028. Its oral suspension packets have patent protection through July 2025. These patents give Novartis the legal right to be the sole seller during that window, eliminating the price competition that typically drives costs down in the pharmaceutical market.
There is one notable development, though. In January 2025, the FDA approved the first generic version of eltrombopag tablets, manufactured by Hetero Labs. That approval currently covers only the ITP indication. Whether this generic reaches pharmacy shelves at a meaningfully lower price, and how quickly, depends on patent litigation outcomes and distribution agreements. But it signals that the era of Promacta as the only option is beginning to close, at least for some patients.
Limited Competition, Even Among Brand-Name Drugs
The main alternative to Promacta for ITP is romiplostim (Nplate), an injectable medication that works through a similar mechanism. But competition between two brand-name drugs doesn’t produce the steep discounts that generic entry does. In fact, romiplostim is even more expensive. A cost analysis published in the Journal of Managed Care & Specialty Pharmacy found that treating one adult ITP patient with romiplostim costs about $64,770 more per year than Promacta, once you factor in drug acquisition, medication waste, and administration fees. Romiplostim’s annual drug cost alone was roughly $183,000 compared to Promacta’s $123,000.
This dynamic actually works against downward pressure on Promacta’s price. When your only real competitor costs even more, there’s little market incentive to lower your own price. Insurance plans comparing the two options see Promacta as the more economical choice, which paradoxically helps justify its six-figure annual cost.
Insurance Hurdles Add to the Burden
Most insurance plans classify Promacta as a specialty medication requiring prior authorization. This means your doctor has to submit documentation proving you meet specific clinical criteria before your plan will cover it. Even within the VA system, which negotiates some of the lowest drug prices in the country, eltrombopag requires local prior authorization.
For patients with commercial insurance, specialty drugs like Promacta typically land on the highest formulary tier, where cost-sharing is calculated as a percentage of the drug’s price (coinsurance) rather than a flat copay. Even a 20% coinsurance rate on a $10,000 monthly prescription leaves you with a $2,000 monthly bill. Some plans cap annual out-of-pocket spending, but reaching that cap can take several months of painful payments.
Patient Assistance Options
Novartis operates a Patient Assistance Foundation (NPAF), an independent nonprofit that provides Promacta at no cost to eligible patients. To qualify, you must live in the United States, be treated by a licensed U.S. healthcare provider on an outpatient basis, and meet income guidelines. The program is designed for people who are uninsured or have government insurance and can’t afford their medication. You’ll need to submit proof of income and, in some cases, evidence that you were denied Extra Help (the federal program that reduces Medicare prescription costs).
One important restriction: the program won’t cover patients whose insurance is tied to “alternate funding programs” that condition coverage on applying to free drug programs. Only you, a legal guardian, or a caregiver can enroll you. Insurance companies, pharmacies, and their representatives are not allowed to submit applications on your behalf.
What Could Change the Price
The biggest factor on the horizon is generic competition. The January 2025 FDA approval of generic eltrombopag tablets is a first step. As patent protections expire through 2028 and more manufacturers enter the market, prices should fall substantially, following the pattern seen with most specialty drugs that lose exclusivity. For the oral suspension formulation, patent expiration in July 2025 could open that market even sooner.
The expiration of Promacta’s remaining orphan drug exclusivity for severe aplastic anemia in November 2025 will also matter. Once that window closes, generic manufacturers can seek approval for that indication too, broadening the competitive landscape beyond ITP. Until then, the combination of small patient populations, strong patent protection, and a market where even the competition costs more will continue to keep Promacta’s price in six-figure territory.